Piper Jaffray Companies initiated coverage on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Friday, MarketBeat reports. The firm issued an overweight rating and a $25.00 price target on the stock.

KURA has been the subject of a number of other research reports. BidaskClub cut shares of Kura Oncology from a sell rating to a strong sell rating in a research note on Wednesday, October 24th. HC Wainwright assumed coverage on shares of Kura Oncology in a research note on Wednesday, August 1st. They set a buy rating and a $31.00 target price for the company. ValuEngine cut shares of Kura Oncology from a strong-buy rating to a buy rating in a research note on Friday, October 19th. Finally, Zacks Investment Research upgraded shares of Kura Oncology from a sell rating to a buy rating and set a $18.00 target price for the company in a research note on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $27.29.

Shares of NASDAQ KURA traded up $0.08 during mid-day trading on Friday, reaching $11.99. 257,032 shares of the company were exchanged, compared to its average volume of 398,285. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.22 and a current ratio of 14.76. The stock has a market cap of $459.87 million, a PE ratio of -7.89 and a beta of 4.39. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $24.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. As a group, analysts predict that Kura Oncology will post -1.73 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC bought a new position in Kura Oncology during the second quarter worth about $187,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Kura Oncology during the second quarter worth about $218,000. Trexquant Investment LP bought a new position in Kura Oncology during the third quarter worth about $217,000. BB&T Securities LLC bought a new position in Kura Oncology during the second quarter worth about $291,000. Finally, Bank of America Corp DE increased its position in Kura Oncology by 327.1% during the second quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock worth $323,000 after acquiring an additional 13,578 shares during the period. 77.28% of the stock is currently owned by institutional investors and hedge funds.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Does the discount rate affect the economy?

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.